{"pmid":32416207,"title":"The risk of respiratory tract infections and symptoms in psoriasis patients treated with IL-17-pathway inhibiting biologics: A meta-estimate of pivotal trials relevant to decision-making during the COVID-19 pandemic.","text":["The risk of respiratory tract infections and symptoms in psoriasis patients treated with IL-17-pathway inhibiting biologics: A meta-estimate of pivotal trials relevant to decision-making during the COVID-19 pandemic.","J Am Acad Dermatol","Wan, Marilyn T","Shin, Daniel B","Winthrop, Kevin L","Gelfand, Joel M","32416207"],"journal":"J Am Acad Dermatol","authors":["Wan, Marilyn T","Shin, Daniel B","Winthrop, Kevin L","Gelfand, Joel M"],"date":"2020-05-17T11:00:00Z","year":2020,"_id":"32416207","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.jaad.2020.05.035","weight":0,"_version_":1666994545926078464,"score":9.490897,"similar":[{"pmid":32314483,"title":"COVID-19 and psoriasis: Should we fear for patients treated with biologics?","text":["COVID-19 and psoriasis: Should we fear for patients treated with biologics?","The new coronavirus pandemic poses question and challenges for dermatologists. One of question is if psoriasis patients treated with immunomodulating and immunosuppressive drugs have to discontinue their treatment in the midst of fears for the infection and its consequences. One of the challenges is how can we support our patients in this critical time. Previous coronaviruses outbreaks reports, current published evidences on pathogenesis and on clinical reports of COVID infection in immunosuppressed patients are used to make a scientifically based decision.","Dermatol Ther","Amerio, Paolo","Prignano, Francesca","Giuliani, Federica","Gualdi, Giulio","32314483"],"abstract":["The new coronavirus pandemic poses question and challenges for dermatologists. One of question is if psoriasis patients treated with immunomodulating and immunosuppressive drugs have to discontinue their treatment in the midst of fears for the infection and its consequences. One of the challenges is how can we support our patients in this critical time. Previous coronaviruses outbreaks reports, current published evidences on pathogenesis and on clinical reports of COVID infection in immunosuppressed patients are used to make a scientifically based decision."],"journal":"Dermatol Ther","authors":["Amerio, Paolo","Prignano, Francesca","Giuliani, Federica","Gualdi, Giulio"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32314483","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1111/dth.13434","keywords":["covid-19","sars","biologics","psoriasis","therapy"],"topics":["Treatment"],"weight":1,"_version_":1666138493540106240,"score":54.955692},{"pmid":32283234,"pmcid":"PMC7146699","title":"Biologics for psoriasis during COVID-19 outbreak.","text":["Biologics for psoriasis during COVID-19 outbreak.","J Am Acad Dermatol","Di Lernia, Vito","32283234"],"journal":"J Am Acad Dermatol","authors":["Di Lernia, Vito"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32283234","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jaad.2020.04.004","keywords":["covid-19","biologics","coronavirus","immunosuppression","psoriasis","treatment"],"topics":["Treatment"],"weight":1,"_version_":1666138491460780032,"score":47.07836},{"pmid":32199889,"pmcid":"PMC7156810","title":"Should biologics for psoriasis be interrupted in the era of COVID-19?","text":["Should biologics for psoriasis be interrupted in the era of COVID-19?","J Am Acad Dermatol","Lebwohl, Mark","Rivera-Oyola, Ryan","Murrell, Dedee F","32199889"],"journal":"J Am Acad Dermatol","authors":["Lebwohl, Mark","Rivera-Oyola, Ryan","Murrell, Dedee F"],"date":"2020-03-23T11:00:00Z","year":2020,"_id":"32199889","source":"PubMed","week":"202013|Mar 23 - Mar 29","doi":"10.1016/j.jaad.2020.03.031","link_comment_in":"32224277","topics":["Treatment"],"weight":1,"_version_":1666138490130137089,"score":44.375114},{"pmid":32283241,"pmcid":"PMC7151252","title":"Reply to: \"Biologics for psoriasis during COVID-19 outbreak\".","text":["Reply to: \"Biologics for psoriasis during COVID-19 outbreak\".","J Am Acad Dermatol","Murrell, Dedee F","Rivera-Oyola, Ryan","Lebwohl, Mark","32283241"],"journal":"J Am Acad Dermatol","authors":["Murrell, Dedee F","Rivera-Oyola, Ryan","Lebwohl, Mark"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32283241","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jaad.2020.04.014","weight":0,"_version_":1666138491498528769,"score":44.375114},{"pmid":32338424,"title":"Biologics for psoriasis in COVID-19 era: what do we know?","text":["Biologics for psoriasis in COVID-19 era: what do we know?","Dermatol Ther","Megna, M","Napolitano, M","Patruno, C","Fabbrocini, G","32338424"],"journal":"Dermatol Ther","authors":["Megna, M","Napolitano, M","Patruno, C","Fabbrocini, G"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32338424","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/dth.13467","keywords":["covid-19","biologics","psoriasis"],"topics":["Prevention"],"weight":1,"_version_":1666138494219583489,"score":44.375114}]}